ArticleThe oncologist2026
Correction to: Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.